

RECEIVED

TECH CENTER 1600/2900

JUL 24 2001

FORM PTO-1449/A and B (Modified)

APPLICATION NO.: 09/355,254

ATTY. DOCKET NO.: C10479005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE: February 22, 2000

APPLICANT: Wagner et al.

GROUP ART UNIT: 1635

EXAMINER: J. Zara

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JZ	A7	5,679,647		Carson et al.	10-21-1997
	A8	5,723,335		Hutcherson et al.	03-03-1998
	A9	5,786,189		Locht et al.	07-28-1998
	A10	6,194,388	B1	Krieg et al.	02-27-2001
	A11	6,207,646	B1	Krieg et al.	03-27-2001
	A12	6,214,804	B1	Felgner et al.	04-10-2001
	A13	6,214,806	B1	Krieg et al.	04-10-2001
	A14	6,218,371	B1	Krieg et al.	04-17-2001
	A15	6,239,116	B1	Krieg et al.	05-29-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
JZ	B18	EPO	0 092 574	B1		11-02-1983	
	B19	WIPO	WO96/02560	A1		02-01-1996	
	B20	WIPO	WO97/28259	A1		08-07-1997	
	B21	WIPO	WO98/16247	A1		04-23-1998	
	B22	WIPO	WO98/55495	A2		12-10-1998	
	B23	WIPO	WO99/51259	A2		10-14-1999	
	B24	WIPO	WO99/56755	A1		11-11-1999	
	B25	WIPO	WO99/58118	A2		11-18-1999	
	B26	WIPO	WO99/61056	A2		12-02-1999	
	B27	WIPO	WO00/06588	A1		02-10-2000	
	B28	WIPO	WO00/14217	A3		03-16-2000	
	B29	WIPO	WO00/67023	A1		11-09-2000	
	B30	WIPO	WO01/22972	A2		04-05-2001	
	B31	WIPO	WO01/22990			04-05-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
JZ	C70	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.		
	C71	BAYEVER E et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. <i>Antisense Res Dev.</i> 1993 Winter;3(4):383-90.		
	C72	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.		
	C73	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med.</i> 1996 Sep;128(3):329-38.		
	C74	BRANDA RF et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. <i>Biochem Pharmacol.</i> 1993 May 25;45(10):2037-43.		

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE: February 22, 2000

APPLICANT: Wagner et al.

GROUP ART UNIT: 1635

EXAMINER: J. Zara

Sheet 2 of 3

TECH CENTER 1600/2900

JUL 24 2001

RECEIVED

83	C75	CHACE JH et al., Regulation of differentiation in CD5+ and conventional B cells. Sensitivity to LPS-induced differentiation and interferon-gamma-mediated inhibition of differentiation. <i>Clin Immunol Immunopathol.</i> 1993 Sep;68(3):327-32.		
	C76	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol.</i> 1990 Jan;64(1):264-77.		
	C77	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med.</i> 1997 Nov 17;186(10):1623-31.		
	C78	COWDERY JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol.</i> 1996 Jun 15;156(12):4570-5.		
	C79	DAVIS HL et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. <i>J Immunol.</i> 1998 Jan 15;160(2):870-6.		
	C80	GRAMZINSKI RA et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. <i>Mol Med.</i> 1998 Feb;4(2):109-18.		
	C81	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol.</i> 1996 Jan 10;167(1):72-8.		
	C82	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol.</i> 1991 Feb;5(2):256-66.		
	C83	KATAOKA T et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82.		
	C84	KLINMAN DM et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i> 1997 Apr 15;158(8):3635-9.		
	C85	KLINMAN DM et al., Immune recognition of foreign DNA: a cure for bioterrorism? <i>Immunity.</i> 1999 Aug;11(2):123-9.		
	C86	KRIEG AM et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? <i>Antisense Res Dev.</i> 1995 Winter;5(4):241.		
	C87	KRIEG AM et al., The role of CpG dinucleotides in DNA vaccines. <i>Trends Microbiol.</i> 1998 Jan;6(1):23-7.		
	C88	KRIEG AM, CpG DNA: a pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol.</i> 1995 Nov;15(6):284-92.		
	C89	KRIEG AM, Leukocyte stimulation by oligodeoxynucleotides. In: <i>Applied Antisense Oligonucleotide Technology</i> , Stein CA and Krieg AM, eds., New York: Wiley-Liss, 1998; pp. 431-438.		
	C90	LIPFORD GB et al., Bacterial DNA as immune cell activator. <i>Trends Microbiol.</i> 1998 Dec;6(12):496-500.		
	C91	LIPFORD GB et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol.</i> 1997 Sep;27(9):2340-4.		
	C92	LIPFORD GB et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol.</i> 1997 Dec;27(12):3420-6.		
	C93	MOLDOVEANU Z et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. <i>Vaccine.</i> 1998 Jul;16(11-12):1216-24.		
	C94	PACA-UCCARALERTKUN S et al., In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax. <i>Mol Cell Biol.</i> 1994 Jan;14(1):456-62.		
	C95	PISETSKY DS et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep.</i> 1993 Oct;18(3):217-21.		
	C96	PISETSKY DS, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev.</i> 1995 Fall;5(3):219-25.		
	C97	PISETSKY DS, The immunologic properties of DNA. <i>J Immunol.</i> 1996 Jan 15;156(2):421-3.		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/355,254	ATTY. DOCKET NO.: C10416605
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: February 22, 2000	
		APPLICANT: Wagner et al.	
		GROUP ART UNIT: 1635	EXAMINER: J. Zara
Sheet 3	of 3		

C98	RAZ E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci U S A.</i> 1996 May 14;93(10):5141-5.		
C99	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.		
C100	SPARWASSER T et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. <i>Eur J Immunol.</i> 1998 Jun;28(6):2045-54.		
C101	SUN S et al., Mitogenicity of DNA from different organisms for murine B cells. <i>J Immunol.</i> 1997 Oct 1;159(7):3119-25.		
C102	THREADGILL DS et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. <i>Vaccine.</i> 1998 Jan;16(1):76-82.		
C103	TSUKADA J et al., Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta gene. <i>Mol Cell Biol.</i> 1994 Nov;14(11):7285-97.		
C104	WEINER GJ et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci U S A.</i> 1997 Sep 30;94(20):10833-7.		
C105	YI AK et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol.</i> 1996 Jan 15;156(2):558-64.		

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED: 12/27/02
------------------------------	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).